Dupilumab Gains Pediatric CSU Approval - Top-Institutions - MDSpire

Dupilumab Gains Pediatric CSU Approval

Targets type 2 inflammation in a population with limited treatment options

  • By

  • Kathryn Wighton

  • April 24, 2026

  • 2 min

Share

Top Institutions in Pediatrics

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Allergy and Infectious Diseases (NIAID), NIH
    National Institute of Allergy and Infectious Diseases (NIAID), NIH

    Bethesda, MD

    Key Differentiators

    • Allergy and Immunology
    • Pediatric Dermatology
    • Clinical Research

  • #2

    Children's Hospital of Philadelphia (CHOP)
    Children's Hospital of Philadelphia (CHOP)

    Philadelphia, PA

    Key Differentiators

    • Pediatric Dermatology
    • Pediatric Allergy and Immunology

  • #3

    Massachusetts General Hospital (MGH) - Pediatric Dermatology and Immunology
    Massachusetts General Hospital (MGH) - Pediatric Dermatology and Immunology

    Boston, MA

    Key Differentiators

    • Pediatric Dermatology
    • Immunology
    • Clinical Trials

  • #4

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Pediatric Allergy and Immunology
    • Dermatology
    • Clinical Research

Original Source(s)

Dupilumab Gains Pediatric CSU Approval

  • by Kathryn Wighton

  • April 24, 2026

Related Content

From anaphylaxis to eosinophilic esophagitis during omalizumab treatment in a boy with severe asthma and food allergy: a case report

Vitamin D May Reflect Myopia Risk

Narrative review linked lower vitamin D levels to greater myopia risk and higher omega-3 intake to lower risk, though outdoor exposure may explain the vitamin D association.

Distribution and associated factors of neck and shoulder pain among primary school children in Shijiazhuang city, Hebei province, China